Mesa Laboratories Stock Price, News & Analysis

Mesa Laboratories, Inc. (NASDAQ: MLAB) has released its inaugural Environmental, Social, and Governance (ESG) Program Brochure on February 13, 2023. The brochure outlines Mesa's ongoing efforts in corporate responsibility and sustainability, emphasizing the company's mission of Protecting the Vulnerable®. Developed by Mesa's ESG Taskforce, the brochure reflects the company's commitment to improving patient care and fostering a sustainable environment for its employees and communities. CEO Gary Owens highlighted the importance of being a net positive contributor to society and the environment. For further details, the brochure can be accessed on the company's website.

Mesa Laboratories (NASDAQ:MLAB) reported its Q3 FY2023 results, revealing a 1% revenue decline to $54,287. Core organic revenue growth stood at 4.6%, despite external pressures such as currency shifts and COVID-related impacts. Operating income surged 235% to $3,402, while net income increased 122% to $451 or $0.08 per diluted share. The Clinical Genomics division was notably affected by the closure of Sema4's expanded carrier screening business, leading to a 10% organic revenue decline. Positive performance was noted in Sterilization & Disinfection Control, with an organic growth of 17.7% for the quarter. Management indicates ongoing cost reductions and a strategy focusing on long-term growth.

Mesa Laboratories, Inc. (NASDAQ: MLAB) declared a quarterly dividend of $0.16 per share, payable on March 15, 2023, to shareholders of record as of February 28, 2023. The company is a leader in the design and manufacturing of life science tools and quality control solutions across pharmaceutical and healthcare sectors. Mesa is committed to ensuring product integrity and enhancing safety and quality of life for customers worldwide.

Mesa Laboratories, Inc. (NASDAQ:MLAB) will announce its third-quarter fiscal 2023 financial results on February 6, 2023, at 8:00 A.M. ET. The company is recognized for its expertise in life science tools and critical quality control solutions across the pharmaceutical, healthcare, and medical device sectors. Mesa operates through four key divisions, delivering products and services aimed at ensuring product integrity and enhancing safety and quality of life globally.

Mesa Laboratories (NASDAQ: MLAB) announced the acquisition of Belyntic GmbH's peptide purification business assets, excluding current assets. This strategic move aims to enhance Mesa's peptide synthesis offerings and support biopharmaceutical development. The transaction is not expected to materially impact Mesa's ongoing operations. The acquisition introduces Belyntic's Peptide Easy Clean Linker, which improves ecological impact by reducing solvent use in peptide purification. Mesa remains focused on quality control solutions for healthcare and medical device sectors.

Mesa Laboratories has appointed Shiraz Ladiwala as the Lead Independent Director of its Board, effective November 3, 2022. This role enhances corporate governance and independent oversight as part of Mesa’s commitment to improved corporate practices. Ladiwala, who has been with the Board since October 2021, is recognized for his significant contributions and leadership capabilities. CEO Gary Owens highlighted Ladiwala's experience in the life science sector as crucial for Mesa's future growth.

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced significant financial results for the second fiscal quarter and six months ended September 30, 2022. Revenues surged 64% to $58.7M for the quarter and 54% to $109.2M year-to-date. Despite the revenue increase, operating income decreased 5% for the quarter and turned negative with a loss of $599K for the six months. Adjusted operating income rose 56% for the quarter, reaching $15.5M. Organic growth was 12% and 8% for the quarter and year-to-date, respectively. The company cited challenges from supply chain issues and currency fluctuations.

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced a quarterly dividend of $0.16 per share, payable on December 15, 2022, to shareholders on record by November 30, 2022. The company, based in Lakewood, Colorado, designs and manufactures life science tools and quality control solutions for the pharmaceutical and healthcare industries. Mesa’s commitment to ensuring product integrity and improving safety highlights its position as a leader in regulated applications within these sectors.

Mesa Laboratories (NASDAQ:MLAB) reported a 44% increase in revenues to $50,453 for 1Q23 compared to 1Q22. However, operating income fell by 247% to $(4,594), and net loss amounted to $(1,438), a 172% decline year-over-year. The adjusted operating income (AOI) dropped 33% to $6,158, influenced by unusual costs of $356. Revenue growth was hindered by China lockdowns and foreign exchange impacts, with organic growth at 3%. Notably, Clinical Genomics faced challenges, while Biopharmaceutical Development showed 24% growth.